Senseonics Holdings Inc. (SENS)
NASDAQ:SENS
Want to see SENS full AI Analyst Report?
Top Page
Senseonics Holdings
(NASDAQ:SENS)
Select Model
Select Model
Rating:49Neutral
Price Target:
$5.50
▼(-18.76% Downside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by weak financial fundamentals (large ongoing losses, heavy cash burn, and weakening leverage/equity) and bearish technicals (trading below major moving averages with negative MACD). These are partially offset by a more positive earnings-call outlook, including raised 2026 revenue guidance and improving gross margin, but near-term cash utilization and execution risk remain significant.
Positive Factors
Revenue & Margin Improvement
Sustained top-line growth and materially higher gross margins improve long-term unit economics for the implantable CGM model. Higher margins increase cash generated per sale and reduce the financing needed to scale, supporting durable commercialization and reinvestment over the next 2–6 months and beyond.
Negative Factors
Large ongoing losses and cash burn
Persistent multi‑year operating losses and negative cash flow materially increase dependence on external capital. Even with revenue momentum, continued high cash burn risks diluting stakeholders, constrains reinvestment capacity, and creates execution pressure if revenue or margin gains slow.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Improvement
Sustained top-line growth and materially higher gross margins improve long-term unit economics for the implantable CGM model. Higher margins increase cash generated per sale and reduce the financing needed to scale, supporting durable commercialization and reinvestment over the next 2–6 months and beyond.
Read all positive factors
Senseonics Holdings (SENS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$329.92M
Dividend YieldN/A
Average Volume (3M)1.01M
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth71.91%
EPS Growth14.73%
CountryUS
Employees117
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.16
Shares Outstanding52,202,965
10 Day Avg. Volume585,549
30 Day Avg. Volume1,013,294
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue7.22
Enterprise Value/Gross Profit13.87
Enterprise Value/Ebitda-3.61
Forecast
1Y Price Target
$16.67Price Target Upside146.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.41
Revenue Forecast (FY)$62.33M
Senseonics Holdings Business Overview & Revenue Model
Company Description
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eve...
How the Company Makes Money
Senseonics primarily makes money by selling its Eversense CGM systems and related supplies and services through commercialization partnerships. Revenue is generated from sales of implantable glucose sensors, external transmitters, and other system...
Senseonics Holdings Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call highlighted strong commercial momentum and validating financial results: Q1 revenue of $11.7M (up 85% YoY), a 58% gross margin, rapid DTC growth (~100% YoY) and successful U.S. commercial integration. Management raised 2026 revenue guidance to $60M–$64M (70%–82% growth) and advanced pipeline milestones (Gemini and Freedom) while adding substantial growth capital ($92M equity + expanded $140M credit facility with a $20M draw). Offsetting these positives are materially higher operating expenses and an expanded net loss driven by in‑house commercialization, significant planned cash burn ($110M–$120M for 2026), increased debt, and remaining execution risk in the European transition and competitive landscape. On balance, the highlights from stronger-than-expected top-line performance, margin expansion and financing to fund growth outweigh the near-term cost and cash challenges, but execution through the rest of 2026 will be key.Positive Updates
Strong Q1 Revenue and Year-over-Year Growth
Net revenue of $11.7 million in Q1 2026, an 85% increase versus $6.3 million in Q1 2025; U.S. revenue $9.3 million and international $2.4 million.
Negative Updates
Higher Operating Expenses and Increased Net Loss
Q1 2026 net loss of $32.3M ($0.71 per share) versus $14.3M ($0.40) in Q1 2025 — an increase of $18.0M; SG&A of $30.2M (up $22.5M year-over-year) driven by commercial integration, transition services and DTC marketing; R&D of $8.6M (up $1.3M).
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Q1 Revenue and Year-over-Year Growth
Net revenue of $11.7 million in Q1 2026, an 85% increase versus $6.3 million in Q1 2025; U.S. revenue $9.3 million and international $2.4 million.
Read all positive updates
Company Guidance
Senseonics raised full‑year 2026 global net revenue guidance to $60–$64 million (from $58–$62M), implying year‑over‑year growth of ~70%–82%; Q1 revenue was $11.7M (up 85% YoY from $6.3M) with gross profit $6.9M and a 58% gross margin (adjusted ~54%), and the company now expects full‑year gross profit margin of 55%–58% with seasonality ~40% H1 / 60% H2. Management guided 2026 operating expenses of $150–$160M and cash utilization of $110–$120M; cash at March 31 was $64.6M, debt and accrued interest $35.2M (total debt outstanding $55M after a $20M draw), the Hercules facility was expanded from $100M to $140M with up to $85M additional availability, and the company raised $92M in gross equity proceeds. Key commercial metrics: planned DTC spend ~ $13M in 2026, DTC drove ~60% of Q1 new patient shipments (HCP ~40%), bundled‑pay now ~60% of volume, reorders expected to be ~40% of U.S. volume, Eon Care performs >1/3 of insertions, and Senseonics expects to double U.S. patients this year.Senseonics Holdings Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.71M | 35.26M | 22.47M | 22.39M | 16.39M | 13.68M |
| Gross Profit | 21.20M | 15.76M | 533.00K | 3.09M | 2.73M | -811.00K |
| EBITDA | -81.50M | -62.65M | -68.70M | -48.01M | 161.81M | -284.51M |
| Net Income | -87.19M | -69.11M | -78.62M | -60.39M | 142.12M | -302.47M |
Balance Sheet | ||||||
| Total Assets | 102.86M | 126.27M | 100.44M | 138.22M | 177.67M | 198.93M |
| Cash, Cash Equivalents and Short-Term Investments | 64.64M | 94.03M | 74.60M | 109.46M | 144.01M | 129.91M |
| Total Debt | 43.14M | 41.37M | 61.05M | 47.78M | 75.38M | 64.21M |
| Total Liabilities | 68.52M | 65.22M | 116.99M | 64.77M | 180.25M | 384.46M |
| Stockholders Equity | 34.34M | 61.05M | -16.55M | 73.45M | -2.58M | -185.53M |
Cash Flow | ||||||
| Free Cash Flow | -75.87M | -60.24M | -62.70M | -70.51M | -66.62M | -56.29M |
| Operating Cash Flow | -75.07M | -59.13M | -60.47M | -70.16M | -66.31M | -56.08M |
| Investing Cash Flow | -10.10M | -53.42M | 32.84M | 89.71M | 26.88M | -148.75M |
| Financing Cash Flow | 75.48M | 78.19M | 26.83M | 20.37M | 41.76M | 220.08M |
Senseonics Holdings Technical Analysis
Positive
6.77
Price Trends
6.33
Positive
6.75
Negative
7.23
Negative
Market Momentum
0.01
Negative
60.28
Neutral
85.60
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Positive. The current price of 6.77 is above the 20-day moving average (MA) of 5.74, above the 50-day MA of 6.33, and below the 200-day MA of 7.23, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 60.28 is Neutral, neither overbought nor oversold. The STOCH value of 85.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SENS.
Senseonics Holdings Risk Analysis
Senseonics Holdings disclosed 69 risk factors in its most recent earnings report. Senseonics Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Senseonics Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $27.11B | 29.94 | 33.83% | ― | 16.15% | 76.15% | |
72 Outperform | $4.06B | 37.29 | 9.13% | ― | 12.40% | ― | |
67 Neutral | $10.11B | 32.97 | 21.38% | ― | 31.93% | -24.86% | |
56 Neutral | $64.52M | 35.99 | 3.68% | ― | -0.32% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $329.92M | -3.53 | -130.00% | ― | 71.91% | 14.73% | |
46 Neutral | $1.02B | -12.10 | -68.29% | ― | 4.54% | 49.66% |
* Healthcare Sector Average
SENS
Senseonics Holdings
6.72
-3.96
-37.07%
DXCM
Dexcom
72.34
-12.52
-14.75%
PODD
Insulet
142.65
-181.20
-55.95%
TNDM
Tandem Diabetes Care
16.72
-4.56
-21.43%
LIVN
LivaNova
73.04
29.87
69.19%
XTNT
Xtant Medical Holdings
0.47
-0.23
-32.76%
Senseonics Holdings Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Senseonics Shareholders Approve Doubling Authorized Common Stock
Positive
May 20, 2026
At its May 20, 2026 annual meeting, Senseonics Holdings stockholders approved doubling the company’s authorized common shares from 70 million to 140 million, a move that expands its capacity to issue equity for financing, acquisitions, or in...
Business Operations and StrategyPrivate Placements and Financing
Senseonics Expands Senior Term Loan Facility to 2029
Positive
May 4, 2026
On May 1, 2026, Senseonics Holdings, Inc. and its subsidiaries entered into a Second Amendment to their Loan and Security Agreement, expanding access to up to $140 million in senior secured term loans maturing on September 3, 2029. The facility in...
Business Operations and StrategyPrivate Placements and Financing
Senseonics Holdings Boosts Capital via Equity and Loan Expansion
Positive
May 1, 2026
On April 30, 2026, Senseonics Holdings, Inc. agreed to sell 8 million shares of common stock and 8 million pre‑funded warrants in an underwritten public offering priced at $5.00 per share, with underwriters holding a 30‑day option to b...
Business Operations and StrategyM&A Transactions
Senseonics Expands European Eversense Operations via Asset Agreements
Positive
Mar 12, 2026
On December 31, 2025, Senseonics entered into a master asset purchase agreement with Ascensia Diabetes Care to acquire assets related to the marketing, sale and distribution of the Eversense CGM product in the U.S., effective January 1, 2026, and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.